A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe restless legs syndrome.

Trial Profile

A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of ropinirole for 26 weeks and to further evaluate the incidence of augmentation and rebound for a further 40 weeks open-label extension treatment period in subjects suffering from moderate to severe restless legs syndrome.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Restless legs syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 May 2010 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
    • 13 Apr 2010 Results presented at the 62nd Annual Meeting of the American Academy of Neurology.
    • 29 Jan 2009 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top